Regulatory Filings • Mar 3, 2025
Regulatory Filings
Open in ViewerOpens in native device viewer
Circio´s leading position in circular RNA therapeutics highlighted by continued broad coverage in international life science industry media
· More than 50 articles and interviews featuring Circio management have been
published in the past year in over 30 widely read EU and US life science
publications, with a combined readership of 14 million
· Circio was invited to publish a comprehensive review article in Nature
Reviews Genetics summarizing the therapeutic potential of circular RNA
· Interviews with CEO Dr Erik Digman Wiklund featured in three prominent
biotech industry podcasts
Oslo, Norway, 3 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, today announces that its strategy to raise awareness of the
therapeutic potential of circular RNA across key life science stakeholders,
continues to deliver broad coverage in top life science and biopharma media.
Over the past year, this effort has resulted in 57 published articles in 33 key
life science industry publications, including three in-depth podcast interviews,
covering recent partnerships, with Certest
Biotec (https://www.circio.com/en/circio-announces-circvec-lnp-delivery
-collaboration-with-certest-progressing-to-in-vivo-testing/) and
4basebio (https://www.circio.com/en/4basebio-partners-with-circio-to-build-and
-test-circvec-synthetic-dna-vectors-for-genetic-medicine-and-vaccines/), and the
launch of the latest circVec generation 3.0. These publications and podcasts
have a combined biopharma following of 14 million stakeholders across the
biopharma sector from biotech and pharma executives and investors to academic
scientists, regulators, and policy think-tanks.
The most prominent recent articles and podcasts include:
The therapeutic potential of circular
RNAs (https://www.nature.com/articles/s41576-024-00806-x)
Nature Reviews Genetics, 9 January 2025
Circio's Vision For Long-Lasting Nucleic Acid Therapeutics
(https://insights.citeline.com/in-vivo/market-intelligence/circios-vision-for
-long-lasting-nucleic-acid-therapeutics-NNX7BEK6PVBPLEBNRBOLKOROTQ/)
InVivo, the Citeline publication, 16 December 2024
Opinion: Circular RNA Will Soon Replace mRNA in
Biopharma (https://www.biospace.com/drug-development/opinion-circular-rna-will
-soon-replace-mrna-in-biopharma)
BioSpace, 31[ ]July 2024
Takeovers, Trump, and trends: how biopharma is likely to shift this
year (https://www.bioxconomy.com/investment/takeovers-trump-and-trends-how
-biopharma-is-shifting-this-year)
BioXconomy, 1 January 2025
Forecasting Pharma's Future (https://www.pharmtech.com/view/drug-solutions
-podcast-forecasting-pharma-s-future)
Drug Solutions podcast, PharmTech, 31 January 2025
Pivoting to RNA with Circio´s Dr. Erik Digman
Wiklund (https://www.youtube.com/watch?v=Iso51hpRf7c&ab_channel=LifeScienceConnec
t)
Business of Biotech podcast, 2 September 2024
"Since emerging from 'stealth mode', we have worked systematically
to communicate our position as discoverers and leaders in the rapidly expanding
circular RNA field," said Erik Digman Wiklund, CEO of Circio. "This effort is
continuing to bear fruit through a substantial number of articles and podcasts
in industry media featuring Circio, as demonstrated in particular by the
invitation to review the circular RNA therapeutics field in the prestigious
scientific journal Nature Reviews Genetics. The broad coverage across multiple
channels builds important visibility and validation for the circVec platform and
its significant potential over conventional mRNA-based expression technology."
The strategy to raise Circio´s profile and circular RNA awareness was initiated
in 2024, following in vivo validation of Circio´s unique and powerful circVec
expression system. Life science communications expert Neil Hunter is supporting
Circio in these efforts through his decades of PR experience for raising
awareness and generating media coverage for therapeutic developers across the
life science sector.
In addition to the cited articles and podcasts, Circio has been covered in
leading industry titles such as Endpoints, BioCentury, BioWorld, The Medicine
Maker, Mergermarket, MedNous, Pharmaceutical Technology, News Medical, Drug
Discovery World, Drug Discovery News, Drug Target Review, Technology Networks,
BioPharma Reporter, News Medical, The Pharma Letter, Contract Pharma, Advancing
RNA, BioPharm International, Pharmaphorum, BioPharma Reporter and Pharma Times.
The combined readership of these titles exceeds 14 million life science
stakeholders globally.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: [email protected]
Neil Hunter - Hunter PR
Phone:+44 7821 255568 (http://tel:+447821255568)
Email: [email protected]
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.